EQ504 / Equillium - LARVOL DELTA

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 (GlobeNewswire) - "Presenters will review preclinical data demonstrating EQ504’s differentiated mechanism of action – enhancing IL-10 and IL-22 signaling, driving regulatory T-cell function, and protecting epithelial barrier integrity – and discuss the company’s plans for a Phase 1 proof-of-mechanism study expected to initiate mid-2026."

New P1 trial • Preclinical • Ulcerative Colitis

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Businesswire) - "...'This funding marks a significant milestone for Equillium, enabling us to accelerate the clinical development of EQ504 into a Phase 1 proof-of-mechanism study in mid-2026, with data expected to follow approximately six months thereafter'."

Financing • New P1 trial • Ulcerative Colitis

Potent AhR Agonist EQ504 Facilitates Gut Epithelial Repair in Inflammatory Disease Models (IMMUNOLOGY 2025) - "EQ504 also induced upregulation of IL-10 expression, a key anti-inflammatory cytokine, thereby highlighting its potential as a therapeutic agent for managing intestinal inflammation and promoting mucosal recovery. These findings demonstrate the efficacy of EQ504 in promoting healing of gut epithelial cells from inflammation and damage, highlighting its potential therapeutic value for patients with inflammatory mucosal diseases.Keywords: Animals Human; Diseases Autoimmunity; Molecules Transcription Factors; Processes Inflammation; Tissues Mucosa"

Inflammation • Inflammatory Bowel Disease • IFNG • IL10 • IL1B • TNFA

EQ504: A Potent Derivative of the AhR Ligand ITE Demonstrates Efficacy in Modulating Inflammation and Promoting Healing in DSS-Colitis (IMMUNOLOGY 2025) - "EQ504 demonstrated superior potency compared to other AhR ligands, with similar efficacy to tapinarof, an FDA-approved AhR topical treatment. In an acute DSS colitis model, EQ504 (1 mg/kg) significantly alleviated clinical symptoms, including body weight loss, colon length reduction, and tissue pathology. These findings highlight the therapeutic potential of EQ504 in treating gut inflammation by modulating immune responses and enhancing tissue repair.Keywords: Animals Rodent; Diseases Autoimmunity; Molecules Transcription Factors; Processes Gene Regulation"

Clinical • Late-breaking abstract • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • AHR • IL10 • IL22

EQ504: A Novel AhR Agonist That Promotes Immune Tolerance Through Modulating T Cell Function (IMMUNOLOGY 2025) - "Conversely, during Th17 differentiation, EQ504 significantly decreased expression of IL-17A and IL-17F while increasing the expression of IL-22, which plays a pivotal role in maintaining barrier function in tissues such as the gut and skin2. EQ504 drives potent Treg stability and function, highlighting AhR modulation as a transformative strategy to rebalance Teff/Treg ratios in immunoinflammatory diseases.Keywords: Animals Human; Cells T Cells; Molecules Cytokines; Processes Cell Activation Tolerance/Suppression/Anergy"

IO biomarker • Inflammation • ENTPD1 • FOXP3 • IL10 • IL17A • IL22 • TIGIT

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Businesswire) - "Equillium, Inc...today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7; EQ504 protects against gut damage in a mouse model of ulcerative colitis;EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses; EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines."

Preclinical • Ulcerative Colitis